Serum thymosin α 1 levels in patients with chronic inflammatory autoimmune diseases

Thymosin alpha 1 (Tα1) is a powerful modulator of immunity and inflammation. Despite years of studies, there are a few reports evaluating serum Tα1 in health and disease. We studied a cohort of healthy individuals in comparison with patients affected by chronic inflammatory autoimmune diseases. Sera from 120 blood donors (healthy controls, HC), 120 patients with psoriatic arthritis (PsA), 40 with rheumatoid arthritis (RA) and 40 with systemic lupus erythematosus (SLE), attending the Transfusion Medicine or the Rheumatology Clinic at the Policlinico Tor Vergata, Rome, Italy, were tested for Tα1 content by means of a commercial enzyme‐linked immunosorbent assay (ELISA) kit. Data were analysed in relation to demographic and clinical characteristics of patients and controls. A gender difference was found in the HC group, where females had lower serum Tα1 levels than males (P < 0·0001). Patients had lower serum Tα1 levels than HC (P < 0·0001), the lowest were observed in PsA group (P < 0·0001 versus all the other groups). Among all patients, those who at the time of blood collection were taking disease‐modifying anti‐rheumatic drugs (DMARD) plus steroids had significantly higher Tα1 levels than those taking DMARD alone (P = 0·044) or no treatment (P < 0·0001), but not of those taking steroids alone (P = 0·280). However, whichever type of treatment was taken by the patients, serum Tα1 was still significantly lower than in HC and there was no treatment‐related difference in PsA group. Further prospective studies are necessary to confirm and deepen these observations. They might improve our understanding on the regulatory role of Tα1 in health and disease and increase our knowledge of the pathogenesis of chronic inflammatory autoimmune diseases.

[1]  M. Paci,et al.  Thymosin α1 Interacts with Exposed Phosphatidylserine in Membrane Models and in Cells and Uses Serum Albumin as a Carrier. , 2016, Biochemistry.

[2]  J. van der Vlag,et al.  Disturbed T Cell Signaling and Altered Th17 and Regulatory T Cell Subsets in the Pathogenesis of Systemic Lupus Erythematosus , 2015, Front. Immunol..

[3]  G. Melino,et al.  The interplay between inflammation and metabolism in rheumatoid arthritis , 2015, Cell Death and Disease.

[4]  M. Paci,et al.  Thymosin α1 inserts N terminus into model membranes assuming a helical conformation , 2015, Expert opinion on biological therapy.

[5]  D. Veale,et al.  What makes psoriatic and rheumatoid arthritis so different? , 2015, RMD Open.

[6]  C. Wallace,et al.  Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis , 2015, Nature Communications.

[7]  M. Chimenti,et al.  Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment , 2014, Clinical and experimental immunology.

[8]  T. Tzai,et al.  Plasma thymosin-α1 level as a potential biomarker in urothelial and renal cell carcinoma. , 2013, Urologic oncology.

[9]  M. Chimenti,et al.  Immunomodulation in psoriatic arthritis: focus on cellular and molecular pathways. , 2013, Autoimmunity reviews.

[10]  E. Garaci,et al.  Thymosin α1 as a stimulatory agent of innate cell‐mediated immune response , 2012, Annals of the New York Academy of Sciences.

[11]  L. Nencioni,et al.  Sex Differences in the Response to Viral Infections: TLR8 and TLR9 Ligand Stimulation Induce Higher IL10 Production in Males , 2012, PloS one.

[12]  Manuel J. Amador-Patarroyo,et al.  Autoimmune disease and gender: plausible mechanisms for the female predominance of autoimmunity. , 2012, Journal of autoimmunity.

[13]  P. Youinou,et al.  Epigenetic alterations and autoimmune disease , 2011, Journal of Developmental Origins of Health and Disease.

[14]  C. Libert,et al.  The X chromosome in immune functions: when a chromosome makes the difference , 2010, Nature Reviews Immunology.

[15]  A. Goldstein,et al.  From lab to bedside: emerging clinical applications of thymosin α1 , 2009 .

[16]  G. Rasi,et al.  Thymosin Alpha 1 , 2007, Annals of the New York Academy of Sciences.

[17]  P. Emery,et al.  The validity of the inclusion of "lupus headache" in the Systemic Lupus Erythematosus Disease Activity Index. , 2007, Arthritis and rheumatism.

[18]  G. Rasi,et al.  Thymosin α1 , 2007 .

[19]  G. Rasi,et al.  Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. , 2006, Blood.

[20]  Dafna Gladman,et al.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study. , 2006, Arthritis and rheumatism.

[21]  Manuel Freire,et al.  Prothymosin α Is Processed to Thymosin α1 and Thymosin α11 by a Lysosomal Asparaginyl Endopeptidase* , 2003, The Journal of Biological Chemistry.

[22]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[23]  J. Guerrero,et al.  Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin α1 and thymulin concentrations: observations in rats and humans , 2000, Journal of Neuroimmunology.

[24]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[25]  van der Heijde Dm,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993 .

[26]  M. Freire,et al.  Thymosin α1 is a native peptide in several tissues , 1992 .

[27]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[28]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[29]  A. Goldstein,et al.  Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha 1. , 1982, Journal of immunology.

[30]  A. Goldstein,et al.  Thymosin administration in autoimmune disorders. , 1981, Thymus.

[31]  A. Guha,et al.  Purification and biological activity of thymosin, a hormone of the thymus gland. , 1972, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[33]  A. Goldstein,et al.  From lab to bedside: emerging clinical applications of thymosin alpha 1. , 2009, Expert opinion on biological therapy.

[34]  E. Garaci,et al.  Combination treatment using thymosin α1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice , 2005, Cancer Immunology, Immunotherapy.

[35]  G. Covelo,et al.  Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase. , 2003, The Journal of biological chemistry.

[36]  M. A. van 't Hof,et al.  Development of a disease activity score based on judgment in clinical practice by rheumatologists. , 1993, The Journal of rheumatology.

[37]  M. Freire,et al.  Thymosin alpha 1 is a native peptide in several tissues. , 1992, Biochimica et biophysica acta.

[38]  A. Goldstein,et al.  Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. , 1991, Viral immunology.